申请人:Glaxo Group Limited
公开号:US05374646A1
公开(公告)日:1994-12-20
The invention provides compounds of the general formula (I) ##STR1## and physiologically acceptable salts, solvates or non-toxic metabolically labile esters thereof where R.sup.1 represents a halogen atom; Ar represents the group ##STR2## R.sup.3 represents a C-linked tetrazolyl group; R.sup.4 and R.sup.5, which may be the same or different, each independently represent a hydrogen atom or a halogen atom or a C.sub.1-6 alkyl group; and Het represents an N-linked imidazolyl group optionally substituted at the 2-position. The compounds may be used in the treatment or prophylaxis of hypertension and diseases associated with cognitive disorders.
该发明提供了一般式(I)的化合物及其生理上可接受的盐、溶剂合物或非毒性代谢易降解酯,其中R.sup.1代表卤素原子;Ar代表该群;R.sup.3代表C-连接的四唑基团;R.sup.4和R.sup.5,可能相同也可能不同,各自独立地代表氢原子或卤素原子或C.sub.1-6烷基团;Het代表N-连接的咪唑基团,可选择地在2-位置上取代。这些化合物可用于治疗或预防高血压和与认知障碍相关的疾病。